Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2020 Genitourinary Cancers Symposium

Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab

Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy

David P. Dearnaley, MD, on Prostate Cancer: Conventional vs Hypofractionated High-Dose Radiotherapy

Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide

Ziad Bakouny, MD, on Metastatic Kidney Cancer: Defining the Role of Cytoreductive Nephrectomy

Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC

Neeraj Agarwal, MD, on Castration-Resistant Prostate Cancer: Results From the COSMIC-021 Study of Cabozantinib and Atezolizumab

Maha Hussain, MD, on Next-Generation Sequencing of Prostate Tumor Tissue: Results From the PROfound Study

Nicholas D. James, PhD, MBBS, on Bladder Cancer: Cetuximab With Chemoradiotherapy

Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide

Thomas Powles, MD, PhD, on Adding Radiation to Immunotherapy for RCC: Improving Systemic Control Through Local Therapy

Nizar M. Tannir, MD, on Nivolumab/Ipilimumab vs Sunitinib in Advanced Kidney Cancer

Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone

Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC

Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Potential Determinants of Poor Prognosis and Treatment Response

Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness


2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors

Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition

Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes

John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy

Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases


2020 Gastrointestinal Cancers Symposium

Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib

Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib

Brian M. Wolpin, MD, on Performance of a Blood-Based Test for the Detection of Multiple Cancers

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy

Zev A. Wainberg, MD, on PD-L1­–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy

Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes

Van K. Morris, MD, on Stage II Colon Cancer: Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy

Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool

Eyal Meiri, MD, on Pembrolizumab in Colorectal Cancer: Results From the TAPUR Study

Thibaud Kössler, MD, PhD, on Localized Rectal Cancer: Neoadjuvant Pembrolizumab and Radiotherapy

Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA

Thomas Yau, MBBS, on Advanced Hepatocellular Carcinoma: CheckMate 040 Trial of Nivolumab, Ipilimumab, and Cabozantinib


2019 San Antonio Breast Cancer Symposium

Rashmi K. Murthy, MD, on HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial of Tucatinib, Capecitabine, and Trastuzumab

Ian E. Krop, MD, PhD, on Trastuzumab Deruxtecan for Patients With Previously Treated, HER2-Positive Metastatic Breast Cancer

Hope S. Rugo, MD, on HER2-Positive Metastatic Breast Cancer: SOPHIA Trial of Chemotherapy Plus Margetuximab or Trastuzumab

Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab

Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine

Icro Meattini, MD, on Breast Irradiation After Breast-Conservation Surgery: 10-Year Follow-up Results

Priyanka Sharma, MD, on Postoperative Treatment of Primary Breast Cancer: POTENT Trial

Nicholas C. Turner, MD, PhD, on ctDNA Testing to Direct Targeted Therapies in Advanced Breast Cancer

Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer

Jack Cuzick, PhD, on the International Breast Cancer Intervention Study II: 10-Year Results

Gerardo Antonio Umanzor Funez, MD, on Metastatic Breast Cancer: Comparing IV and Oral Formulations of Paclitaxel

Rowan T. Chlebowski, MD, PhD, on Breast Cancer: Findings From The Women’s Health Initiative

Ralph R. Weichselbaum, MD, on Oligometastatic Cancer: The Role of Radioimmunotherapy

Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors

Belinda Kingston, MB ChB, on the Genomic Landscape of Breast Cancer Based on ctDNA Analysis

Joseph Sparano, MD: The William L. McGuire Memorial Lecture

Javier Cortes, MD, PhD, on Triple-Negative Breast Cancer: Results From the KEYNOTE-119 Trial of Pembrolizumab vs Chemotherapy

Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy

Madeleine M.A. Tilanus-Linthorst, MD, PhD, on MRI vs Mammography: Comparing Cost and Effectiveness

Ariella B. Hanker, PhD, on Therapeutic Implications of HER2 and HER3 Mutations in Breast Cancer

Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Omitting Breast Surgery: Results of the MICRA Trial

Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence

Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide

Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer

Luca Gianni, MD, on the Neoadjuvant Treatment of Triple-Negative Breast Cancer

Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer

Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays


2019 ASH Annual Meeting & Exposition

Patrick A. Brown, MD, on B-Cell ALL in Children, Adolescents, and Young Adults: Blinatumomab vs Chemotherapy

Andrew H. Wei, MBBS, PhD, on AML: Results From the QUAZAR Trial on Oral Azacitidine

Saad Z. Usmani, MD, on Carfilzomib, Dexamethasone, and Daratumumab for Relapsed or Refractory Myeloma

Ilaria Iacobucci, PhD, on AML and MDS: Moving Beyond Gene Panel–Based Classifications

Edward A. Stadtmauer, MD, on Advanced Multiple Myeloma and Sarcoma: First-in-Human Assessment of CRISPR-Edited T Cells

Mikkael A. Sekeres, MD, on Newly Diagnosed Hematologic Malignancies: Early Trial Findings on Glasdegib Plus Azacitidine

Loretta J. Nastoupil, MD, on Follicular Lymphoma: Trial Results With Obinutuzumab/Lenalidomide

Nitin Jain, MD, on First-Line Ibrutinib Plus Venetoclax in CLL

Mhairi Copland, PhD, MB BChir, on Blast Phase CML: A Possible Treatment Advance

Tait D. Shanafelt, MD, on CLL in Younger Patients: Comparing Ibrutinib and Rituximab With FCR

David P. Steensma, MD, on Myeloid Neoplasms: Results From a First-in-Human Trial of a Splicing Modulator

Catherine M. Diefenbach, MD, on Follicular Lymphoma: Polatuzumab Vedotin Plus Obinutuzumab/Lenalidomide

Jennifer Crombie, MD, on Relapsed or Refractory CLL/SLL: Results From a Phase I Trial of Duvelisib and Venetoclax

Mark Bustoros, MD, on Ixazomib/Lenalidomide/Dexamethasone for High-Risk Smoldering Multiple Myeloma

Jerald P. Radich, MD, on CML: Predicting Deep Molecular Response to Treatment

C. Ola Landgren, MD, PhD, on Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab for Newly Diagnosed Multiple Myeloma

Jeff P. Sharman, MD, on CLL: Trial Results on Acalabrutinib, Obinutuzumab, and Chlorambucil


NCCN 2019 Annual Congress: Hematologic Malignancies

Andrew D. Zelenetz, MD, PhD, on The Era of Therapeutic Biosimilars: What You Need to Know

William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL

Nitin Jain, MD, on CLL: Is There a Role for Chemoimmunotherapy?

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Rafael Bejar, MD, PhD, on Myelodysplastic Syndromes: Advances in Personalized Therapeutic Approaches

Jorge J. Castillo, MD, on Evolution of Therapy for Relapsed/Refractory Multiple Myeloma


ESMO 2019 Congress

Antonio González Martín, MD, PhD, on Ovarian Cancer: PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib

Isabelle Ray-Coquard, MD, PhD, on Ovarian Cancer: Olaparib Plus Bevacizumab

Suresh S. Ramalingam, MD, on Osimertinib vs Comparator EGFR TKI in EGFR-Mutated NSCLC: The FLAURA Trial

Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers

Thomas Powles, MD, PhD, and Enrique Grande, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: KEYNOTE-522 Trial of Pembrolizumab Plus Chemotherapy

Véronique Diéras, MD, on HER2-Negative, BRCA-Mutated Breast Cancer: Veliparib Plus Carboplatin/Paclitaxel

Laura Q.M. Chow, MD, on Metastatic NSCLC: Results of the ASCEND-7 Trial on Ceritinib

Ghassan K. Abou-Alfa, MD, MBA, on Cholangiocarcinoma: ClarIDHy Trial of Ivosidenib vs Placebo

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Sherene Loi, MD, PhD, and Leisha A. Emens, MD, PhD, on HER2-Positive Breast Cancer: KATE2 Study of Atezolizumab/Trastuzumab Emtansine

Paolo A. Ascierto, MD, on Melanoma: Results From CheckMate 238 on Adjuvant Nivolumab vs Ipilimumab

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Olaparib/Enzalutamide/Abiraterone

Robin L. Jones, MD, MBBS, on Advanced Angiosarcoma: TAPPAS Trial of a Novel Monoclonal Antibody Plus Pazopanib

Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer

Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial

Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma

Thomas Powles, MD, PhD, on Metastatic Urothelial Cancer: Durvalumab Plus Targeted Treatments

Tim Meyer, PhD, and Lorenza Rimassa, MD, on Advanced Hepatocellular Carcinoma: CELESTIAL Trial of Cabozantinib

Volker Kunzmann, MD, on Advanced Pancreatic Cancer: Findings on nab-Paclitaxel/Gemcitabine and FOLFIRINOX

Sungjune Kim, MD, PhD, on Merkel Cell Carcinoma: Nivolumab/Ipilimumab Plus SBRT

Georgina V. Long, MD, PhD, on Melanoma Brain Metastases: Nivolumab Alone or Nivolumab/Ipilimumab

Ana Maria Arance Fernandez, MD, PhD, on Advanced Melanoma: Treatment With Cobimetinib/Atezolizumab vs Pembrolizumab

Mansoor R. Mirza, MD, on Ovarian Cancer: Roundup of ESMO 2019 Top Abstracts

Nicoletta Colombo, MD, on Lenvatinib/Pembrolizumab for Advanced Endometrial Cancer

Nicholas D. James, PhD, MBBS, on Prostate Cancer: STAMPEDE Trial M1|RT Comparison of Radiotherapy


2019 ASTRO Annual Meeting

Andreas Rimner, MD, on the PACIFIC Trial: Durvalumab for Stage III NSCLC

Daniel E. Spratt, MD, on the Impact of Antiandrogen Treatment in Prostate Cancer: NRG Oncology/RTOG 9601 Trial

Steven H. Lin, MD, PhD, on Esophageal Cancer: Proton Beam vs Intensity-Modulated Radiation Therapy

Justin Barnes, MS, on the Affordable Care Act and Risk of Suicide in Patients With Cancer

Ryan Phillips, MD, PhD, on Oligometastatic Prostate Cancer: ORIOLE Trial on Observation vs Stereotactic Ablative Radiation

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: HERA Trial on Postmastectomy Radiation Therapy

Daniel M. Trifiletti, MD, on Optimizing Whole-Brain Radiotherapy Dose and Fractionation for Patients With Brain Metastases

David Routman, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV Circulating Tumor DNA

Alejandra Méndez Romero, MD, PhD, on Liver Metastases: Dutch-Belgian Registry of Stereotactic Body Radiation

Sue Sun Yom, MD, PhD, on Oropharyngeal Cancer: Deintensifying Radiation Therapy Plus Chemotherapy

Michael J. LaRiviere, MD, on Non-Hodgkin Lymphoma: Induction Radiation Before CAR T-Cell Therapy for Resistant Disease

Erica H. Bell, PhD, on Low-Grade Gliomas: Subgroup Analysis of the NRG Oncology/RTOG 9802 Trial

Robert Olson, MD, on Quality-of-Life Outcomes After Stereotactic Ablative Radiotherapy vs Standard-of-Care Palliative Treatments

Andrew Kneebone, MD, on an ANZUP Trial on Adjuvant vs Early Salvage Radiotherapy After Prostatectomy


2019 Quality Care Symposium

Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value

Karen M. Winkfield, MD, PhD, on Policy and Business Solutions to Address Disparities in Cancer Care

Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival

Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial

Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials

Elena Martinez, PhD, MPH, on Diversity in Precision Oncology

Grace C. Hillyer, EdD, MPH, on Enrolling Patients in Clinical Trials: Improving Clinician-Patient Communication

Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs

Lauren M. Hamel, PhD, on Race and Doctor-Patient Behavior

Angela M. Stover, PhD, on Patient-Reported Outcome Performance Measures for Oncology Practice

Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual and Gender Minorities

Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists

Joseph O. Jacobson, MD, on Suffering, Systems, and Safety: The Joseph V. Simone Award Lecture

Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?

Manali I. Patel, MD, on Community Practices: Enhancing Delivery of Value-Based Cancer Care

Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review


2019 ASCO Annual Meeting

Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion

Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy

Ian D. Davis, MBBS, PhD, and Christopher Sweeney, MBBS, on Prostate Cancer: ENZAMET Trial on Enzalutamide for Metastatic Hormone-Sensitive Disease

Sara A. Hurvitz, MD, on HR+/HER2− Advanced Breast Cancer: MONALEESA-7 Trial on Endocrine Therapy With or Without Ribociclib

Josep Tabernero, MD, PhD, on Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Pembrolizumab With or Without Chemotherapy vs Chemotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

Kamal Chamoun, MD, on Multiple Myeloma: Insurance Status and Survival

Richard L. Schilsky, MD, and R. Donald Harvey, PharmD, BCOP, on Advanced Non–Small Cell Lung Cancer: Expanding the Criteria for Clinical Trial Eligibility

William D. Tap, MD, on Soft-Tissue Sarcomas: ANNOUNCE Trial on Doxorubicin and Olaratumab

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Richard Pazdur, MD, on the Launch of Project Facilitate

Lee S. Schwartzberg, MD, FACP: 2019 Update on the ACCC Immuno-Oncology Institute: Using Immunotherapy in the Community Setting

Kamran A. Ahmed, MD, on Cervical Cancer: Stereotactic Body Radiation Therapy Plus Atezolizumab

Manmeet S. Ahluwalia, MD, on Glioblastoma: Novel Cancer Vaccine With Standard Therapy

Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation

Margaret A. Tempero, MD, on Pancreatic Cancer: Adjuvant Nab-paclitaxel and Gemcitabine

Mark J. Levis, MD, PhD, on Acute Myeloid Leukemia: Gilteritinib in FLT3-Mutated Disease

Karim Fizazi, MD, PhD, on the ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

Rowan T. Chlebowski, MD, PhD, on Breast Cancer Incidence and Mortality: Results From the Women’s Health Initiative on the Effects of a Low-Fat Diet

Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin

David J. Kwiatkowski, MD, PhD, on Non–Small Cell Lung Cancer: Neoadjuvant Immunotherapy for Resectable Disease

Daniel P. Petrylak, MD, on Urothelial Cancer: Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Disease

Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy

Neeraj Agarwal, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: KEYNOTE-426 on First-Line Pembrolizumab Plus Axitinib vs Sunitinib

Neeraj Agarwal, MD, and Arnaud Méjean, MD, PhD, on Renal Cancer: Cytoreductive Nephrectomy Followed by Sunitinib in the Metastatic Setting

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Adding Bevacizumab to Gemcitabine and Cisplatin

Matt D. Galsky, MD, on Urothelial Cancer: Pembrolizumab vs Placebo After First-Line Chemotherapy

Suresh S. Ramalingam, MD, on Non–Small Cell Lung Cancer: Pemetrexed, Bevacizumab, or Both as Maintenance Therapy

Yoland C. Antill, MD, on Endometrial Cancer: PHAEDRA Trial on Durvalumab and Mismatch Repair Status

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, and Zachery Reichert, MD, PhD, on Prostate Cancer: Focal Radiation for Oligometastatic Castration-Resistant Disease

Paul G. Richardson, MD, on Relapsed or Refractory Multiple Myeloma: Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

Thomas J. George, MD, on Locally Advanced Rectal Cancer: Total Neoadjuvant Therapy

Brian C. Baumann, MD, on Locally Advanced Cancer: Proton vs Photon Therapy

Brian C. Baumann, MD, on Locally Advanced Bladder Cancer: Adjuvant Radiotherapy After Radical Cystectomy

Michael J. Morris, MD, on Metastatic Prostate Cancer: Adding Abiraterone Acetate to Enzalutamide

Ziad Bakouny, MD, and Toni K. Choueiri, MD, on Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease

Kim N. Chi, MD, on Castration-Resistant Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in the Metastatic Setting

Kim N. Chi, MD, on Metastatic Castration-Sensitive Prostate Cancer: First Results From the TITAN Trial

Francesca Gay, MD, on Multiple Myeloma: Carfilzomib/Lenalidomide/Dexamethasone With or Without Transplantation

Michael A. Thompson, MD, PhD, on Smoldering Multiple Myeloma: Reassessing Risk Stratification Models

Gilberto Lopes, MD, MBA, on the RELAY Trial in Metastatic NSCLC: Erlotinib and Ramucirumab in EGFR Mutant–Positive Disease

Richard T. Penson, MD, and Don S. Dizon, MD, on Ovarian Cancer: SOLO3 Trial on Olaparib vs Chemotherapy in Relapsed Disease

Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil

Panagiotis A. Konstantinopoulos, MD, PhD, on Endometrial Cancer: Avelumab in Microsatellite-Stable and -Instable Disease

Sagar Lonial, MD, on Smoldering Multiple Myeloma: Delaying Disease Progression With an Immunomodulatory Agent

Javier Sastre, MD, PhD, on Colorectal Cancer: Bevacizumab and FOLFOXIRI in Metastatic Disease

Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b

Yeon Hee Park, MD, on Metastatic Breast Cancer: Palbociclib, Exemestane, and GnRH Agonist

William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004

Kerry A. Rogers, MD, on Chronic Lymphocytic Leukemia: Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed or Refractory Disease

Jame Abraham, MD, on NALA Trial Findings in HER2-Positive Metastatic Breast Cancer

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine

Matthew A. Powell, MD, and Don S. Dizon, MD, on Uterine or Ovarian Cancer: Paclitaxel Plus Carboplatin vs Ifosfamide in Chemotherapy-Naive Patients

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: KRISTINE Trial on Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy

Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, on ANZUP: Taking a Multidisciplinary Approach to Prostate, Kidney, Bladder, Testicular, and Penile Cancers

Leonard J. Appleman, MD, PhD, on Metastatic Renal Cell Carcinoma: Pazopanib vs Placebo After Metastasectomy

Matteo Lambertini, MD, PhD, on Safety of Pregnancy After Treatment for BRCA-Mutated Breast Cancer

Joseph A. Sparano, MD, on Early Breast Cancer: Predicting Prognosis and Treatment Benefit in TAILORx

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor

Mansoor Raza Mirza, MD, and Don S. Dizon, MD, on Recurrent Platinum-Sensitive Ovarian Cancer: Niraparib Plus Bevacizumab

Hani M. Babiker, MD, on Tumor Treating Fields: A Different Approach to Therapy

Åsmund A. Fretland, MD, on Colorectal Cancer Liver Metastases: Laparoscopic vs Open Resection

Hope S. Rugo, MD, and Matteo Lambertini, MD, PhD, on the SOPHIA Trial in HER2-Positive Metastatic Breast Cancer: Chemotherapy Plus Margetuximab vs Trastuzumab

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Atezolizumab Plus Nab-paclitaxel

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Breast Cancer: Next Steps in Immunotherapy

François-Xavier Mahon, MD, PhD, on Chronic-Phase Chronic Myeloid Leukemia: Treatment-Free Remission After Second-Line Treatment


NCCN Annual Conference 2019

Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: New Immunotherapy Strategies in the NCCN Guidelines

Eric Jonasch, MD, on Kidney Cancer: A Year in Review

Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer

Neil P. Shah, MD, PhD, on CML: NCCN Guidelines Updates on Discontinuing Tyrosine Kinase Inhibitor Therapy

Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals

Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates

James L. Mohler, MD, on Managing Prostate Cancer: NCCN Guidelines Updates

Michelle B. Riba, MD, on Screening for Distress in Cancer: Implementing the Standard of Care

Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update

Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice


2019 Multidisciplinary Thoracic Cancers Symposium

Leora Horn, MD, on Small Cell Lung Cancer and Immuno-oncology: Have We Finally Solved the Small Cell Paradox?

Heather A. Wakelee, MD, on Advanced Non–Small Cell Lung Cancer: State-of-the-Art Treatment for EGFR-Positive and ALK-Positive Diseases

Aaron S. Mansfield, MD, on Treating Rare Thoracic Cancers: Status Update

Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease

J. Fletcher Drogos, MD, on Multiple Courses of Stereotactic Body Radiation Therapy: Outcomes in Patients With Lung Cancer

Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Survival Outcomes and Clinical and Molecular Features

Martin Edelman, MD, on Immunotherapy: How Safe Is It for Patients With Autoimmune Disease?

Jing Zeng, MD, on Non–Small Cell Lung Cancer: Therapeutic Implications of Proper Disease Staging

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments


2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Toni K. Choueiri, MD, and Ziad Bakouny, MD, on Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Predicting Response to PD-1 Inhibitors With cfDNA

Madhav V. Dhodapkar, MBBS, on Cancer Vaccines: Emerging Trends

Kim A. Margolin, MD, on Promising Immunotherapy Strategies

Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab

G. Travis Clifton, MD, on Breast Cancer and Disease Recurrence: Final Analysis From a Study of Nelipepimut-S, GM-CSF, and Trastuzumab

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Stefan O. Ciurea, MD, on Infusing High Doses of Natural Killer Cells: An Enhanced Antitumor Effect

Advertisement

Advertisement



Feb
28
Today In Oncology
Vitamin D May Reduce Risk for Immune Checkpoint Inhibitor–Associated Colitis
Do Socioeconomic Factors Play a Role in Outcomes for HPV-Positive Head and Neck Cancer
Women With Variants in Breast Cancer–Associated Genes May Not Always Be Receiving Guideline-Concordant Care
Circulating Tumor Cell Assessment to Predict Melanoma Relapse
Incidence Increases in New Colorectal Cancer Diagnoses in Patients Between 49 and 50 Years Old
View More 
Advertisement
Most Read Stories
Value: Is the Benefit Worth the Cost?
Late Mortality and Chronic Health Conditions in Long-Term Survivors of AYA Cancers
Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Disease Progression on EGFR Tyrosine Kinase Inhibitors
Living My Best Life
No Improved Pathologic Complete Response With Atezolizumab in Early Triple-Negative Breast Cancer
View More 
© 2020 HSP News Service, L.L.C.